Within the EMPULSE trial, patients were initially stabilized and subsequently randomized; hence, SGLT2 inhibitor therapy was established in a median duration of 72 h, whereas, in the EMPAG-HF trial, SGLT2 inhibitors were introduced within a 12-h timeframe after hospital admission [12]. This evidence concerns the gene SLC5A2 and hydrops fetalis.